Company facts
OncoLattice Bio: company facts
Patient feasibility. Site selection. Decisions grounded in the questions your trial needs answered.
Discuss a feasibility question
What is OncoLattice Bio?
OncoLattice Bio provides independent patient and site feasibility support for biotech sponsors, with a focus on oncology clinical development. We work with teams in China, the US and global programs.
What does OncoLattice do?
We help define the relevant patient population, examine site and investigator evidence, assess competing-trial context, and identify priorities and unanswered questions for site validation and enrollment planning.
What are the core capabilities?
Patient feasibility, site feasibility, clinical trial site selection, PI/site prioritization, enrollment feasibility, and competitive-trial/site context. Deliverables and validation activities are agreed for each program.
How is OncoLattice different from a CRO?
We focus on independent sponsor-side feasibility analysis and decision support. The sponsor retains final decisions, while clinical teams and CROs retain their agreed trial-execution responsibilities. We are not a full-service CRO, generic AI consultancy, out-licensing adviser or regulatory consultancy.
Does OncoLattice support China NMPA programs?
Yes, our scope can support patient and site feasibility questions in China NMPA clinical trial planning. This does not mean regulatory filing, regulatory representation or a guarantee of approval. Project scope, available evidence and execution responsibilities must be confirmed.
Does OncoLattice support US and global trials?
Yes. Patient and site feasibility, investigator prioritization and competing-trial context can support US and global planning. Data access, local requirements and the need for site validation are assessed for the specific program; a single analysis does not establish coverage of every country.
What evidence matters for site selection?
Protocol-specific patient fit and pathways; relevant trial and investigator experience; diagnostics and treatment capabilities; competing studies and team capacity; and practical startup constraints. Data-derived candidates are not verified sites or guaranteed enrollable patients. Unresolved questions require appropriate site/CRO follow-up.
Published by OncoLattice Bio. This page describes our service scope, not independent certification or evidence of clinical results.
Explore service scopes →